Kavanaugh A, Gottlieb A, Morita A, et al. - Through the SPIRIT-P1 and SPIRIT-P2 are phase 3 trials that examined ixekizumab, an interleukin-17A antagonist, in the treatment of 402 patients with active psoriatic arthritis (PsA), the researchers discovered the contribution of joint and skin improvements to health-related quality of life (HRQoL) in patients with PsA. individuals with PsA had baseline psoriasis of ≥ 3% of body surface area. Response surface modeling to this patient data set was applied in order to examine the correlation between the Disease Activity Index for Psoriatic Arthritis (DAPSA), Psoriasis Area and Severity Index (PASI) and HRQoL improvements at week 24. In both DAPSA and PASI together rather than DAPSA or PASI alone, the greatest improvement in the European Quality of Life-Five Dimensions Visual Analogue Score was correlated with the greatest percent improvements. In domains of Short-Form Health Survey and Work Productivity and Activity Impairment, comparable remarks were made. Hence, in patients’ HRQoL, optimal improvements were reliant on the victorious treatment of both joint and skin symptoms.